Be Aware of New Warnings for Janus Kinase Inhibitors (Xeljanz, etc)

Patients may present to your emergency department with adverse effects from Janus kinase (JAK) inhibitors...tofacitinib (Xeljanz), etc.

These oral meds are used for autoimmune diseases, such as rheumatoid arthritis and ulcerative colitis.

Now there's a boxed warning about an increased risk of thromboembolism with tofacitinib. The JAK inhibitors baricitinib (Olumiant) and upadacitinib (Rinvoq) also carry this warning.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals